Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingNot applicable2024-03-08NCT06053099

1 results · Page 1 of 1

Swipe the table sideways for more columns.

36 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Angers - CHUAngersFrance9
Annecy - CHPringyFrance2
Bayonne - CHBayonneFrance2
Bordeaux - CHUPessacFrance7
Boulogne - Ambroise ParéBoulogneFrance3
Caen - CHUCaenFrance6
Clermont-Ferrand - CHUClermont-FerrandFrance4
Colmar - CHColmarFrance4
Créteil - CHICréteilFrance6
Dijon - CHU BocageDijonFrance4
Grenoble - CHUGrenobleFrance7
La Roche-Sur-Yon - CHLa Roche-sur-YonFrance1
Le Mans - CHGLe MansFrance10
Lille - CHULilleFrance4
Lyon - CRLCCLyonFrance1
Lyon - URCOTBronFrance1
Marseille - APHMMarseilleFrance6
Metz - Hôpital Robert SchumanMetzFrance3
Montpellier - CHUMontpellierFrance6
Montpellier - ICMMontpellierFrance1
Nice - CHUNiceFrance1
Orléans - CHROrléansFrance3
Paris - BichatParisFrance4
Paris - HEGPParisFrance1
Paris - Hôpital CochinParisFrance5